Tag Archives: chronic disease
By Foti Panagakos, DMD, PhD, global director of scientific affairs at Colgate-Palmolive
Oral health has been demonstrated to be associated with, and an important influencer of, overall health. The role of prevention is critical to reducing, and eventually eliminating what the WHO has deemed an epidemic, caries or cavities in teeth. This is the most prevalent disease among children, with more than 60% of 5 year olds having at least one cavity. In addition, research over the last 25 years has shown that in patients who have a chronic disease, such as diabetes or cardiovascular disease, and concomitant serious gum or periodontal disease, the treatment of the oral disease will improve the control and management of the systemic chronic disease.
While these findings have stimulated action among the medical and dental communities to work collaboratively in identifying and treating oral disease in these very vulnerable patients, it is the fact that the oral disease is preventable in the first place which should take precedence in our management of this problem. Developing and implementing preventative technologies is the solution to addressing both of these issues. Continue reading →
When it comes to prevention of chronic disease, what one policy change would have the greatest impact on moving from “promise” to “results?”
by Mary Woolley, Research!America President and CEO. This entry was originally posted as a guest contribution to PhRMA’s Conversations forum.
A shift in attitude among elected officials is necessary if this nation is to succeed in combating disease and stemming the rise of health care costs. Federal funding for the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and other agencies that conduct medical and health research has not kept pace with scientific opportunity, jeopardizing our ability to find cures for deadly disease and to maintain our global competitive edge. Medical research has not risen to the upper ranks of our nation’s priorities in the halls of Congress; advocacy from stakeholders is critical to changing this.
Underfunded federal agencies that should be providing the catalyst for private sector innovation to help bend the cost curve are instead forced to cut and cut. Even as federal funding diminishes, the burden of disease rages on, exacting a tremendous financial and emotional toll on patients and families stressed by learning of delays in the next phase of promising research that could one day lead to cures. And not only are our elected officials giving too little attention to key federal agencies, they are not prioritizing policy-making that will incentivize the private sector to accelerate the development of new treatments and therapies for patients. There is a lot of talk about the value of innovation, but not a lot of action to stimulate it. Continue reading →